FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Sridhar Mani

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Procedures

Anatomy

Tumor Cell Line

Co-author Network

Publications

TOP 3
Umang Swami; Sanjay Goel; Sridhar Mani
Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case for Prophylaxis.
Sridhar Mani; Wei Dou; Matthew R Redinbo
PXR antagonists and implication in drug metabolism.
Razelle Kurzrock; François Lokiec; Sridhar Mani; Sonia K Morgan-Linnell; Aby Buchbinder; Imran Chaudhary; Siqing Fu; Mohammed H Ghalib; Sanjay Goel; David Hong; Keyvan Rezai; Saik Urien; Jennifer Wheler; Mary Mulcahy
Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Sridhar Mani (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Umang Swami; Sanjay Goel; Sridhar Mani
Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case for Prophylaxis.
Current drug targets 2013;14(7):777-97.
2013: Sridhar Mani; Wei Dou; Matthew R Redinbo
PXR antagonists and implication in drug metabolism.
Drug metabolism reviews 2013;45(1):60-72.
2012: Razelle Kurzrock; François Lokiec; Sridhar Mani; Sonia K Morgan-Linnell; Aby Buchbinder; Imran Chaudhary; Siqing Fu; Mohammed H Ghalib; Sanjay Goel; David Hong; Keyvan Rezai; Saik Urien; Jennifer Wheler; Mary Mulcahy
Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies.
Cancer 2012;118(24):6144-51.
2012: Patricia M LoRusso; Sridhar Mani; Daniel Mulkerin; Rachel Neuwirth; Ramesh K Ramanathan; Michelle A Rudek; John Sarantopoulos; Stephen I Shibata; Chris H Takimoto; Karthik Venkatakrishnan; Afshin Dowlati; Dixie Esseltine; Anne Hamilton; Percy Ivy
Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(10):2954-63.
2012: Elaine T Lam; Sridhar Mani; Barbara McCracken; Larry J Schaaf; Gillian F Cropp; SANJAY GOEL; Brandi I Haley; Alison L Hannah; Robert G Johnson; Yiqing Zhou; Miguel A Villalona-Calero
Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2012;69(2):523-31.
2011: Johnson Ming-Yu Liu; Jeffrey M Lipton; Sridhar Mani
Sixth International Congress on Shwachman-Diamond syndrome: from patients to genes and back.
Annals of the New York Academy of Sciences 2011;1242():26-39.
2011: Lucie Krausova; Sridhar Mani; Lucie Stejskalova; Radim Vrzal; Hongwei Wang; Zdenek Dvorak; Petr Pavek
Metformin suppresses pregnane X receptor (PXR)-regulated transactivation of CYP3A4 gene.
Biochemical pharmacology 2011;82(11):1771-80.
2011: Ticiana B Leal; Heinz-Josef Lenz; Patricia M LoRusso; Sridhar Mani; James Mier; Angela Davies; Merrill J Egorin; Anne Hamilton; S Percy Ivy; Rachel Neuwirth; Ramesh K Ramanathan; Scot C Remick; John Sarantopoulos; Stephen Shibata; Chris H Takimoto; Karthik Venkatakrishnan; Lisa von Moltke; John J Wright; Daniel Mulkerin
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
Cancer chemotherapy and pharmacology 2011;68(6):1439-47.
2011: Jeff L Staudinger; Chenshu Xu; Arunima Biswas; Sridhar Mani
Post-translational modification of pregnane x receptor.
Pharmacological research : the official journal of the Italian Pharmacological Society 2011;64(1):4-10.
2011: Arunima Biswas (Basu); Danielle Pasquel; Rakesh Kumar Tyagi; Sridhar Mani
Acetylation of pregnane X receptor protein determines selective function independent of ligand activation.
Biochemical and biophysical research communications 2011;406(3):371-6.
2010: Nicola F Smith; Sridhar Mani; Erin G Schuetz; Kazuto Yasuda; Tristan M Sissung; Susan E Bates; William D Figg; Alex Sparreboom
Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2.
The Annals of pharmacotherapy 2010;44(11):1709-17.
2010: Radharani Gollamudi; Mohammad H Ghalib; Kavita K Desai; Imran Chaudhary; Benny Wong; Mark Einstein; Matthew Coffey; George M Gill; Karl Mettinger; John M Mariadason; Sridhar Mani; SANJAY GOEL
Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors.
Investigational new drugs 2010;28(5):641-9.
2010: Sridhar Mani; U Swami
Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer.
Drugs of today (Barcelona, Spain : 1998) 2010;46(9):641-53.
2010: Subhajit Mukherjee; Sridhar Mani
Orphan nuclear receptors as targets for drug development.
Pharmaceutical research 2010;27(8):1439-68.
2010: Anthony P Lam; Joseph A Sparano; Vincent Vinciguerra; Allyson J Ocean; Paul Christos; Howard Hochster; Fernando Camacho; SANJAY GOEL; Sridhar Mani; Andreas Kaubisch
Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma.
American journal of clinical oncology 2010;33(2):121-4.
2010: Velasco Cimica; Melissa E Smith; Zhikai Zhang; Deepti Mathur; Sridhar Mani; Ganjam V Kalpana
Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen.
BMC cancer 2010;10():634.
2009: Bhaskar Das; venkatesh madhukumar; Jaime Anguiano; Sridhar Mani
Design, synthesis and biological evaluation of 2H-benzo[b][1,4] oxazine derivatives as hypoxia targeted compounds for cancer therapeutics.
Bioorganic & medicinal chemistry letters 2009;19(15):4204-6.
2009: Arunima Biswas (Basu); Sridhar Mani; Matthew R Redinbo; Matthew D Krasowski; Hao Li; Ekins Sean
Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists.
Pharmaceutical research 2009;26(8):1807-15.
2009: SANJAY GOEL; Catalin Mita; Monica Mita; Eric K Rowinsky; Quincy S Chu; Nancy Wong; Christopher Desjardins; Fang Fang; Mendel Jansen; Dale E Shuster; Sridhar Mani; Chris H Takimoto
A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(12):4207-12.
2009: Sridhar Mani; Mohammed Ghalib; Imran Chaudhary; SANJAY GOEL
Alterations of chemotherapeutic pharmacokinetic profiles by drug-drug interactions.
Expert opinion on drug metabolism & toxicology 2009;5(2):109-30.
2009: Divya Gupta; Sridhar Mani
The efficacy and safety of ixabepilone monotherapy in the treatment of breast and gynecologic malignancies.
Expert opinion on drug safety 2009;8(1):81-8.
2008: SANJAY GOEL; Gary L Goldberg; Dennis Kuo; F Muggia; Joseph C Arezzo; Sridhar Mani
Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(12):2048-52.
2008: Kyriakos P Papadopoulos; SANJAY GOEL; Muralidhar Beeram; Alvin Wong; Kavita Desai; Missak Haigentz; María L Milián; Sridhar Mani; Anthony W Tolcher; Alshad S Lalani; John Sarantopoulos
A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(21):7110-5.
2008: Radharani Gollamudi; Divya Gupta; SANJAY GOEL; Sridhar Mani
Novel orphan nuclear receptors-coregulator interactions controlling anti-cancer drug metabolism.
Current drug metabolism 2008;9(7):611-3.
2008: Divya Gupta; venkatesh madhukumar; Hongwei Wang; Sean Kim; Michael Sinz; Gary L Goldberg; Kathleen D Whitney; Clifford Longley; Sridhar Mani
Expanding the roles for pregnane X receptor in cancer: proliferation and drug resistance in ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(17):5332-40.
2008: Sean Ekins; Vladyslav Kholodovych; Ni Ai; Michael Sinz; Joseph Gal; Lajos Gera; WILLIAM J WELSH; Kenneth Bachmann; Sridhar Mani
Computational discovery of novel low micromolar human pregnane X receptor antagonists.
Molecular pharmacology 2008;74(3):662-72.
2008: Bhaskar Das; venkatesh madhukumar; Jaime Anguiano; Sean Kim; Michael Sinz; Tatyana A Zvyaga; Eoin C Power; C Robin Ganellin; Sridhar Mani
Synthesis of novel ketoconazole derivatives as inhibitors of the human Pregnane X Receptor (PXR; NR1I2; also termed SXR, PAR).
Bioorganic & medicinal chemistry letters 2008;18(14):3974-7.
2008: SANJAY GOEL; Marvin Cohen; S Nilgün Cömezoglu; Lionel Perrin; François André; David Jayabalan; Lisa Iacono; Adriana Comprelli; Van T Ly; Donglu Zhang; Carrie Xu; W Griffith Humphreys; Hayley M McDaid; Gary L Goldberg; Susan B. Horwitz; Sridhar Mani
The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(9):2701-9.
2008: Sridhar Mani
Agranulocytosis induced by nonchemotherapy drugs.
Annals of internal medicine 2008;148(4):320; author reply 320-1.
2008: Joseph Gibbons; Merrill J Egorin; Ramesh K Ramanathan; Pingfu Fu; Daniel Mulkerin; Stephen Shibata; Chris H Takimoto; Sridhar Mani; Patricia M LoRusso; Jean L Grem; Anna Pavlick; Heinz-Josef Lenz; Susan M Flick; Sherrie Reynolds; Theodore F Lagattuta; Robert A Parise; Yanfeng Wang; Anthony J Murgo; S Percy Ivy; Scot C Remick
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(4):570-6.
2008: Melissa E Smith; Velasco Cimica; Srinivasa Chinni; Kavitha Challagulla; Sridhar Mani; Ganjam V Kalpana
Rhabdoid tumor growth is inhibited by flavopiridol.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(2):523-32.
2007: SANJAY GOEL; Robert J Bauer; Kavita Desai; Anca Bulgaru; T Iqbal; B-K Strachan; G Kim; Andreas Kaubisch; G F Vanhove; Gary L Goldberg; Sridhar Mani
Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineere monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(10):1704-7.
2007: Sean Ekins; Cheng Chang; Sridhar Mani; Matthew D Krasowski; Erica J Reschly; Manisha Iyer; Vladyslav Kholodovych; Ni Ai; WILLIAM J WELSH; Michael Sinz; Peter Swaan; Rachana Patel; Kenneth Bachmann
Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites.
Molecular pharmacology 2007;72(3):592-603.
2007: Chris H Takimoto; Martin A Graham; Graham Lockwood; Chee M Ng; Andrew Goetz; Dennis Greenslade; Scot C Remick; Sunil Sharma; Sridhar Mani; Ramesh K Ramanathan; Timothy W Synold; James Doroshow; Anne Hamilton; Daniel Mulkerin; Percy Ivy; Merrill J Egorin; Jean L Grem
Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(16):4832-9.
2007: Timothy W Synold; Chris H Takimoto; James Doroshow; David R Gandara; Sridhar Mani; Scot C Remick; Daniel Mulkerin; Anne Hamilton; Sunil Sharma; Ramesh K Ramanathan; Heinz-Josef Lenz; Martin Graham; Jeff Longmate; Bennett M Kaufman; Percy Ivy
Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(12):3660-6.
2007: SANJAY GOEL; Kavita Desai; Sirisha Karri; Radharani Gollamudi; Imran Chaudhary; Anca Bulgaru; Andreas Kaubisch; Gary L Goldberg; Mark Einstein; Fernando Camacho; Sharyn Baker; Sridhar Mani
Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers.
Investigational new drugs 2007;25(3):237-45.
2007: Hongwei Wang; Haiyan Huang; Hao Li; Denise G Teotico; Michael Sinz; Sharyn D Baker; Jeffrey Staudinger; Ganjam V Kalpana; Matthew R Redinbo; Sridhar Mani
Activated pregnenolone X-receptor is a target for ketoconazole and its analogs.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(8):2488-95.
2007: Gregory A Otterson; Miguel A Villalona-Calero; Sunil Sharma; Mark G Kris; Anthony Imondi; Mirjam Gerber; Dorothy A White; Mark J Ratain; Joan H Schiller; Alan B Sandler; Michael Kraut; Sridhar Mani; John R Murren
Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(4):1246-52.
2007: Minaxi Jhawer; Lee Rosen; Janet Dancey; Howard Hochster; Solomon Hamburg; Margaret A Tempero; Neil Clendeninn; Sridhar Mani
Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma.
Investigational new drugs 2007;25(1):85-94.
2007: Haiyan Huang; Hongbing Wang; Michael Sinz; M Zoeckler; J Staudinger; Matthew R Redinbo; Denise G Teotico; Joseph Locker; Ganjam V Kalpana; Sridhar Mani
Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole.
Oncogene 2007;26(2):258-68.
2007: Sridhar Mani; Hayley M McDaid; A Grossman; Franco Muggia; SANJAY GOEL; T Griffin; D Colevas; Susan B. Horwitz; Merrill J Egorin
Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(1):190-5.
2006: Maria V Nesterova; Natalie Johnson; Chris Cheadle; Susan E Bates; Sridhar Mani; Constantine Straturis; Islam U Khan; Islam Kahn; Rishab K Gupta; Yoon S Cho-Chung
Autoantibody cancer biomarker: extracellular protein kinase A.
Cancer research 2006;66(18):8971-4.
2006: Minaxi Jhawer; Sridhar Mani; Myrto Lefkopoulou; Richard G Hahn; Jules Harris; Paul J Catalano; Daniel Haller
Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: An eastern cooperative oncology group study E7282.
Investigational new drugs 2006;24(5):447-54.
2006: William C Zamboni; Ramesh K Ramanathan; howard mcleod; Sridhar Mani; Douglas M Potter; Sandra Strychor; Lauren J Maruca; Cristi R King; Laura L Jung; Robert A Parise; Merrill J Egorin; Todd A Davis; Sharon Marsh
Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes.
Investigational new drugs 2006;24(5):393-401.
2006: William C Zamboni; SANJAY GOEL; Tahir Iqbal; Robert A Parise; Sandra Strychor; Trisha V W Repinski; Merrill J Egorin; Sridhar Mani
Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors.
Cancer chemotherapy and pharmacology 2006;57(5):631-9.
2006: Ramesh K Ramanathan; Marwan G Fakih; Sridhar Mani; Melvin Deutsch; Raymond P Perez; Mark A Ritter; Julie L Eiseman; S Percy Ivy; Donald L Trump; Chandra P Belani; Robert A Parise; Douglas M Potter; Merrill J Egorin
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers.
Cancer chemotherapy and pharmacology 2006;57(4):465-74.
2006: SANJAY GOEL; Kavita Desai; Manuel Macapinlac; Scott Wadler; Gary L Goldberg; Abbie Fields; Mark Einstein; Fabio Volterra; Benny Wong; Russell Martin; Sridhar Mani
A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers.
Investigational new drugs 2006;24(2):125-34.
2006: D Alarcon-Vargas; Z Zhang; B Agarwal; K Challagulla; Sridhar Mani; Ganjam V Kalpana
Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors.
Oncogene 2006;25(5):722-34.
2005: Cy A Stein; Luba Benimetskaya; Sridhar Mani
Antisense strategies for oncogene inactivation.
Seminars in oncology 2005;32(6):563-72.
2005: Hedy L Kindler; Peter K Tothy; Robert Wolff; Richard A McCormack; James L Abbruzzese; Sridhar Mani; Kurombi Wade-Oliver; Everett E Vokes
Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers.
Investigational new drugs 2005;23(5):489-93.
2005: Apurva A Desai; Hedy L Kindler; David A Taber; Edem Agamah; Sridhar Mani; Kurombi Wade-Oliver; Mark J Ratain; Everett E Vokes
Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer.
Cancer chemotherapy and pharmacology 2005;56(4):421-6.
2005: Sridhar Mani; Haiyan Huang; Sumathy Sundarababu; Wenjing Liu; Ganjam V Kalpana; Amos B Smith; Susan B. Horwitz
Activation of the steroid and xenobiotic receptor (human pregnane X receptor) by nontaxane microtubule-stabilizing agents.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(17):6359-69.
2005: Kongming Wu; Mark D'Amico; Chenguang Wang; Chris Albanese; Richard G Pestell; Sridhar Mani
A study of cytotoxic synergy of UCN-01 and flavopiridol in syngeneic pair of cell lines.
Investigational new drugs 2005;23(4):299-309.
2004: Cathy Eng; Ramesh K Ramanathan; Ramesh K Ramathan; Michael K Wong; Scot C Remick; Lanting Dai; Kurombi Wade-Oliver; Sridhar Mani; Hedy L Kindler
A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma.
American journal of clinical oncology 2004;27(6):565-9.
2004: Federico Innocenti; Samir D Undevia; Jacqueline Ramírez; Sridhar Mani; Richard L Schilsky; Nicholas J Vogelzang; Marisol Prado; Mark J Ratain
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.
Clinical pharmacology and therapeutics 2004;76(5):490-502.
2004: Samir D Undevia; Nicholas J Vogelzang; Ann M Mauer; Linda Janisch; Sridhar Mani; Mark J Ratain
Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.
Investigational new drugs 2004;22(4):449-58.
2004: Sai Latha Shankar; Melissa Krupski; Bhupesh Parashar; Chidi Okwuaka; Kathleen O'Guin; Sridhar Mani; Bridget Shafit-Zagardo
UCN-01 alters phosphorylation of Akt and GSK3beta and induces apoptosis in six independent human neuroblastoma cell lines.
Journal of neurochemistry 2004;90(3):702-11.
2004: Hedy L Kindler; Anjali Avadhani; Kurombi Wade-Oliver; Theodore Karrison; Sridhar Mani; Everett E Vokes
9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium.
Investigational new drugs 2004;22(3):323-7.
2004: Sridhar Mani; Manuel Macapinlac; SANJAY GOEL; Dominik Verdier-Pinard; Tito Fojo; Mace Rothenberg; Dimitrios Colevas
The clinical development of new mitotic inhibitors that stabilize the microtubule.
Anti-cancer drugs 2004;15(6):553-8.
2004: Sridhar Mani; Hayley M McDaid; Anne Hamilton; Howard Hochster; Marvin B Cohen; Dineo Khabelle; Tom Griffin; David E Lebwohl; Leonard Liebes; Franco Muggia; Susan B. Horwitz
Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(4):1289-98.
2004: Neil Senzer; Sridhar Mani; Alexander Rosemurgy; John Nemunaitis; Casey Cunningham; Chandan Guha; Natalia Bayol; Michelle Gillen; Karen Chu; Camilla Rasmussen; Henrik Rasmussen; Donald Kufe; Ralph Weichselbaum; Nadar N Hanna
TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(4):592-601.
2003: Sridhar Mani; SANJAY GOEL; Maria V Nesterova; R M Martin; J M Grindel; M L Rothenberg; R Zhang; G Tortora; Yoon S Cho-Chung
Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM 231) targeted against protein kinase A type I.
Annals of the New York Academy of Sciences 2003;1002():252-62.
2003: SANJAY GOEL; A Bulgaru; Howard Hochster; Scott Wadler; William C Zamboni; Merrill J Egorin; Percy Ivy; L Leibes; Franco Muggia; Graham Lockwood; E Harvey; G Renshaw; Sridhar Mani
Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(11):1682-7.
2003: SANJAY GOEL; Kavita Desai; Anca Bulgaru; Abbie Fields; Gary L Goldberg; Sudhir Agrawal; Russell Martin; Michael Grindel; Sridhar Mani
A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(11):4069-76.
2003: Chris H Takimoto; Scot C Remick; Sunil Sharma; Sridhar Mani; Ramesh K Ramanathan; James Doroshow; Anne Hamilton; Daniel Mulkerin; Martin Graham; Graham F Lockwood; Percy Ivy; Merrill J Egorin; Dennis Greenslade; Andrew Goetz; Jean L Grem
Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group.
Seminars in oncology 2003;30(4 Suppl 15):20-5.
2003: James Doroshow; Timothy W Synold; David R Gandara; Sridhar Mani; Scot C Remick; Daniel Mulkerin; Anne Hamilton; Sunil Sharma; Ramesh K Ramanathan; Heinz-Josef Lenz; Martin Graham; Jeff Longmate; Chris H Takimoto; Percy Ivy
Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group.
Seminars in oncology 2003;30(4 Suppl 15):14-9.
2003: M Aklilu; Hedy L Kindler; Ross C Donehower; Sridhar Mani; Everett E Vokes
Phase II study of flavopiridol in patients with advanced colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(8):1270-3.
2003: Chris H Takimoto; Scot C Remick; Sunil Sharma; Sridhar Mani; Ramesh K Ramanathan; James Doroshow; Anne Hamilton; Daniel Mulkerin; Martin Graham; Graham F Lockwood; Percy Ivy; Merrill J Egorin; Barbara Schuler; Dennis Greenslade; Andrew Goetz; Ronald Knight; Rebecca Thomas; Brian P Monahan; William Dahut; Jean L Grem
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(14):2664-72.
2003: Anca Bulgaru; Sridhar Mani; SANJAY GOEL; Roman Perez-Soler
Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase.
Expert review of anticancer therapy 2003;3(3):269-79.
2003: WenJing Liu; Anca Bulgaru; Missak Haigentz; Cy A Stein; Roman Perez-Soler; Sridhar Mani
The BCL2-family of protein ligands as cancer drugs: the next generation of therapeutics.
Current medicinal chemistry. Anti-cancer agents 2003;3(3):217-23.
2003: Della Makower; Joseph A Sparano; Scott Wadler; Karen Fehn; Leon Landau; Paul Wissel; Melissa Versola; Sridhar Mani
A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma.
Cancer investigation 2003;21(2):177-84.
2003: Corina E Akerele; Irina Rybalova; Howard Kaufman; Sridhar Mani
Current approaches to novel therapeutics in pancreatic cancer.
Investigational new drugs 2003;21(1):113-29.
2003: SANJAY GOEL; Scott Wadler; Anthony Hoffman; Fabio Volterra; Cheryl Baker; Elliot Nazario; Percy Ivy; Alyson Silverman; Sridhar Mani
A phase II study of rebeccamycin analog NSC 655649 in patients with metastatic colorectal cancer.
Investigational new drugs 2003;21(1):103-7.
2003: Gregory A Masters; Bruce E Brockstein; Sridhar Mani; Mark J Ratain
Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.
Medical oncology (Northwood, London, England) 2003;20(1):7-12.
2002: SANJAY GOEL; Minaxi Jhawer; Lakshmi Rajdev; Una Hopkins; Karen Fehn; Cheryl Baker; Hoo G Chun; Della Makower; Leon Landau; Anthony Hoffman; Scott Wadler; Sridhar Mani
Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies.
American journal of clinical oncology 2002;25(5):528-34.
2002: Kongming Wu; Chenguang Wang; Mark D'Amico; Richard J Lee; Chris Albanese; Richard G Pestell; Sridhar Mani
Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.
Molecular cancer therapeutics 2002;1(9):695-706.
2002: Hayley M McDaid; Sridhar Mani; Heng-Jia Shen; Franco Muggia; Daryl Sonnichsen; Susan B. Horwitz
Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2035-43.
2002: Dale R Shepard; Sridhar Mani; Helen Kastrissios; Susan Learned-Coughlin; Deborah Smith; Phillip Ertel; Steve Magnum; Linda Janisch; Gini F Fleming; Richard L Schilsky; Mark J Ratain
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil.
Cancer chemotherapy and pharmacology 2002;49(5):398-402.
2002: Sridhar Mani; Charles Rudin; Katie Kunkel; Jon T Holmlund; Richard S Geary; Hedy L Kindler; F Andrew Dorr; Mark J Ratain
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(4):1042-8.
2002: Sridhar Mani; Martin A Graham; David B Bregman; Percy Ivy; Stephen G Chaney
Oxaliplatin: a review of evolving concepts.
Cancer investigation 2002;20(2):246-63.
2002: SANJAY GOEL; Sridhar Mani; Roman Perez-Soler
Tyrosine kinase inhibitors: a clinical perspective.
Current oncology reports 2002;4(1):9-19.
2001: Yi Lu; Sridhar Mani; E R Kandimalla; D Yu; S Agrawal; J.Christopher States; David B Bregman
The Cockayne syndrome group B DNA repair protein as an anti-cancer target.
International journal of oncology 2001;19(6):1089-97.
2001: Sai Latha Shankar; Sridhar Mani; Kathleen O'Guin; E R Kandimalla; S Agrawal; Bridget Shafit-Zagardo
Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways.
Journal of neurochemistry 2001;79(2):426-36.
2001: Sridhar Mani; Nicholas J Vogelzang; Donna Bertucci; Walter M Stadler; Richard L Schilsky; Mark J Ratain
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Cancer 2001;92(6):1567-76.
2001: Anand K Sharma; Sridhar Mani; Nadar N Hanna; Chandan Guha; B Vikram; R R Weichselbaum; Joseph A Sparano; B Sood; David Lee; William F Regine; M Muhodin; Joseph Valentino; JOSEPH HERMAN; Philip Desimone; S Arnold; J Carrico; Anna Rockich; J Warner-Carpenter; M Barton-Baxter
Clinical protocol. An open-label, phase I, dose-escalation study of tumor necrosis factor-alpha (TNFerade Biologic) gene transfer with radiation therapy for locally advanced, recurrent, or metastatic solid tumors.
Human gene therapy 2001;12(9):1109-31.
2001: Charles Rudin; Jon T Holmlund; Gini F Fleming; Sridhar Mani; Walter M Stadler; Phil L Schumm; Brett P Monia; JF Johnston; Richard S Geary; Zhengrong Yu; T Jesse Kwoh; F Andrew Dorr; Mark J Ratain
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(5):1214-20.
2001: Reginald Ewesuedo; Lalitha Iyer; Soma Das; A Koenig; Sridhar Mani; Nicholas J Vogelzang; Richard L Schilsky; W Brenckman; Mark J Ratain
Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(7):2084-90.
2001: Chenguang Wang; Maofu Fu; Sridhar Mani; S Wadler; A M Senderowicz; Richard G Pestell
Histone acetylation and the cell-cycle in cancer.
Frontiers in bioscience : a journal and virtual library 2001;6():D610-29.
2001: B C Goh; Mark J Ratain; Donna Bertucci; R Smith; Sridhar Mani; Nicholas J Vogelzang; Richard L Schilsky; M Hutchison; M Smith; Steven Averbuch; E Douglass
Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1476-84.
2001: Sridhar Mani
UGT1A1 polymorphism predicts irinotecan toxicity: evolving proof.
AAPS pharmSci 2001;3(3):2.
2000: Sridhar Mani; J Manalo; D Bregman
Novel combinations with oxaliplatin.
Oncology (Williston Park, N.Y.) 2000;14(12 Suppl 11):52-8.
2000: Sridhar Mani; C Wang; K Wu; R Francis; R Pestell
Cyclin-dependent kinase inhibitors: novel anticancer agents.
Expert opinion on investigational drugs 2000;9(8):1849-70.
2000: Richard L Schilsky; M Eileen Dolan; Donna Bertucci; Reginald Ewesuedo; Nicholas J Vogelzang; Sridhar Mani; Lynette R Wilson; Mark J Ratain
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(8):3025-31.
2000: Sridhar Mani; H Hochster; T Beck; E M Chevlen; M A O'Rourke; C H Weaver; W N Bell; R White; C McGuirt; Jeremey Levin; JA Hohneker; Richard L Schilsky; J Lokich
Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(15):2894-901.
2000: Alan P Venook; Merrill J Egorin; Gary Rosner; Donna Hollis; Sridhar Mani; M Hawkins; John Byrd; R Hohl; D Budman; N J Meropol; Mark J Ratain
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(14):2780-7.
2000: Howard Kaufman; WA Conkright; Joseph DiVito; Heidi Hörig; Ronald Kaleya; David Lee; Sridhar Mani; Dennis Panicali; Lakshmi Rajdev; T S Ravikumar; S Wise-Campbell; M J Surhland
A phase I trial of intra lesional RV-B7.1 vaccine in the treatment of malignant melanoma.
Human gene therapy 2000;11(7):1065-82.
2000: Richard L Schilsky; R Bukowski; Howard A Burris; H Hochster; M O'Rourke; J G Wall; Sridhar Mani; T Bonny; Jeremey Levin; JA Hohneker
A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(4):415-20.
2000: DF Amanatullah; Anne T Reutens; Brian T Zafonte; Maofu Fu; Sridhar Mani; Richard G Pestell
Cell-cycle dysregulation and the molecular mechanisms of prostate cancer.
Frontiers in bioscience : a journal and virtual library 2000;5():D372-90.
1999: Sridhar Mani; Y Gu; S Wadler; H Fingert
Antisense therapeutics in oncology: points to consider in their clinical evaluation.
Antisense & nucleic acid drug development 1999;9(6):543-7.
1999: Everett E Vokes; B C Goh; Donna Bertucci; Nicholas J Vogelzang; Sridhar Mani; Mark J Ratain
A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors.
Cancer 1999;86(3):528-32.
1999: Sridhar Mani; David F Sciortino; Brian L Samuels; R Arrietta; Richard L Schilsky; Everett E Vokes; S Benner
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma.
Investigational new drugs 1999;17(1):97-101.
1999: Mark DeMario; Mark J Ratain; Nicholas J Vogelzang; Sridhar Mani; Everett E Vokes; Gini F Fleming; K Melton; S Johnson; S Benner; D Lebwohl
A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days.
Cancer chemotherapy and pharmacology 1999;43(5):385-8.
1998: Sridhar Mani; John W Kugler; David F Sciortino; JC Garcia; Rafat H Ansari; Rod A Humerickhouse; Fabrizio Michelassi; Mitchell C Posner; KL Shulman; Richard L Schilsky; Marcy A List; Everett E Vokes; S Benner
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(9):1035-7.
1998: Nicholas J Vogelzang; Sridhar Mani; Richard L Schilsky; Rafat H Ansari; David A Taber; S N Rhinehart; JC Garcia; S C Meyer; R Mick; Bruce E Brockstein; Walter M Stadler; Mark J Ratain; Everett E Vokes
Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(4):929-34.
1998: Sridhar Mani; T Schiano; JC Garcia; Rafat H Ansari; B Samuels; David F Sciortino; S Tembe; KL Shulman; A Baker; S E Benner; Everett E Vokes
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced hepatocellular carcinoma.
Investigational new drugs 1998;16(3):279-83.
1998: Sridhar Mani; John W Kugler; James A Knost; David F Sciortino; J Gibbons; JC Garcia; Rafat H Ansari; Richard L Schilsky; Everett E Vokes
Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer.
Investigational new drugs 1998;16(3):275-8.
1998: Sridhar Mani; Lalitha Iyer; Linda Janisch; X Wang; Gini F Fleming; Richard L Schilsky; Mark J Ratain
Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071).
Cancer chemotherapy and pharmacology 1998;42(1):84-7.
1997: Sridhar Mani
UFT plus leucovorin in advanced hepatobiliary tumors and pancreatic adenocarcinomas.
Oncology (Williston Park, N.Y.) 1997;11(9 Suppl 10):124-7.
1997: Sridhar Mani; Mark J Ratain
New phase I trial methodology.
Seminars in oncology 1997;24(2):253-61.
1996: Sridhar Mani; Mark J Ratain
Promising new agents in oncologic treatment.
Current opinion in oncology 1996;8(6):525-34.
1996: Sridhar Mani; N J Vogelzang
Is "off-protocol" chemotherapy for androgen-independent carcinoma of prostate warranted?
Hematology/oncology clinics of North America 1996;10(3):749-68.
1996: Sridhar Mani; M Todd; WJ Poo
Recombinant beta-interferon in the treatment of patients with metastatic renal cell carcinoma.
American journal of clinical oncology 1996;19(2):187-9.
1996: Sridhar Mani; WJ Poo
Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma.
American journal of clinical oncology 1996;19(2):149-53.
1995: Yue Wang; James F Holland; Ira J Bleiweiss; Stella M Melana; X Liu; I Pelisson; A Cantarella; K Stellrecht; Sridhar Mani; Beatriz G T Pogo
Detection of mammary tumor virus env gene-like sequences in human breast cancer.
Cancer research 1995;55(22):5173-9.
1995: Sridhar Mani; T P Duffy
Anemia of pregnancy.
Clinics in perinatology 1995;22(3):593-607.
1995: Sridhar Mani; M B Todd; K Katz; WJ Poo
Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.
The Journal of urology 1995;154(1):35-40.
1994: Sridhar Mani; T P Duffy
Pericardial tamponade in chronic myelomonocytic leukemia.
Chest 1994;106(3):967-70.
1994: Sridhar Mani; Irvin M Modlin; G Ballantyne; H Ahlman; B West
Carcinoids of the rectum.
Journal of the American College of Surgeons 1994;179(2):231-48.
1994: Sridhar Mani; G J Smith
HIV and pulmonary hypertension: a review.
Southern medical journal 1994;87(3):357-62.
1993: Sridhar Mani; Stuart D Flynn; T P Duffy; W Morgan
Isolated amyloidosis of the penile urethra and corpus spongiosum: a case report.
The Journal of urology 1993;150(6):1915-6.
1993: Sridhar Mani; M Barry; John Concato
Granulocyte-colony stimulating factor therapy in drug-induced agranulocytosis.
Archives of internal medicine 1993;153(21):2500-1.
1993: Sridhar Mani; T P Duffy
Sickle myonecrosis revisited.
The American journal of medicine 1993;95(5):525-30.
1993: Antonio C Buzaid; Alan B Sandler; Sridhar Mani; A M Curtis; WJ Poo; J L Bolognia; S Ariyan
Role of computed tomography in the staging of primary melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(4):638-43.
1993: Sridhar Mani; Abraham G Kocheril; V T Andriole
Case report: pentamidine and polymorphic ventricular tachycardia revisited.
The American journal of the medical sciences 1993;305(4):236-40.
1993: Irvin M Modlin; Marc D Basson; Sridhar Mani
Diagnosis and management of gastrointestinal neuroendocrine tumors.
The Gastroenterologist 1993;1(1):59-70.